Literature DB >> 23607672

Prescription drug abuse: a comparison of prescriber and pharmacist perspectives.

Nicholas E Hagemeier1, Jeffrey A Gray, Robert P Pack.   

Abstract

This study compared perceptions of prescribers and pharmacists (N = 89) regarding multiple aspects of prescription drug abuse. Questionnaires were developed to assess perceptions regarding the prevalence of prescription drug abuse, self-perceived communication competence, and additional communication and prescription drug abuse domains. Pharmacists perceived a larger percentage of patients (41%) to be abusing opioid pain relievers as compared with their prescriber colleagues (17%). Both prescribers and pharmacists indicated improvements in prescriber-pharmacist communication would serve to deter prescription drug abuse. Self-efficacy beliefs for detecting and discussing prescription drug abuse with patients were low for both cohorts. Implications and limitations are noted. Year of data collection: 2012
SETTING: Rural Appalachia Data Collection Instruments: Prescriber- and pharmacist-specific survey instruments Data Analysis Techniques: Independent samples t-test; Mann-Whitney U test.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607672     DOI: 10.3109/10826084.2013.787101

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  12 in total

1.  Provider-patient communication about prescription drug abuse: A qualitative analysis of the perspective of prescribers.

Authors:  Stephanie M Mathis; Angela Hagaman; Nicholas Hagemeier; Katie Baker; Robert P Pack
Journal:  Subst Abus       Date:  2019-08-12       Impact factor: 3.716

2.  Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis.

Authors:  Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Brittany Ratliff; Angela Hagaman; Robert P Pack
Journal:  Subst Abus       Date:  2017-09-15       Impact factor: 3.716

3.  The Harnessing Online Peer Education (HOPE) Intervention for Reducing Prescription Drug Abuse: A Qualitative Study.

Authors:  Sean D Young; Keith Heinzerling
Journal:  J Subst Use       Date:  2017-01-31

4.  Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors.

Authors:  Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Angela Hagaman; Robert P Pack
Journal:  Res Social Adm Pharm       Date:  2015-12-29

5.  Pharmacists' Role in Opioid Safety: A Focus Group Investigation.

Authors:  Daniel M Hartung; Jennifer Hall; Sarah N Haverly; David Cameron; Lindsey Alley; Christi Hildebran; Nicole O'Kane; Deborah Cohen
Journal:  Pain Med       Date:  2018-09-01       Impact factor: 3.750

6.  An evaluation of Alberta pharmacists' practices, views and confidence regarding prescription drug abuse and addiction within their practice setting.

Authors:  Candace Necyk; Ken Cor; Arianna Mazzuca; Lauren Meleshko
Journal:  Can Pharm J (Ott)       Date:  2019-08-13

Review 7.  Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product.

Authors:  Joseph V Pergolizzi; Robert Taylor; Jo Ann LeQuang; Robert B Raffa
Journal:  J Pain Res       Date:  2018-02-08       Impact factor: 3.133

8.  Pharmacist Services in the Opioid Crisis: Current Practices and Scope in the United States.

Authors:  Tanvee Thakur; Meredith Frey; Betty Chewning
Journal:  Pharmacy (Basel)       Date:  2019-06-13

9.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

10.  Mapping Community Opioid Exposure Through Wastewater-Based Epidemiology as a Means to Engage Pharmacies in Harm Reduction Efforts.

Authors:  Claire Duvallet; Bryan D Hayes; Timothy B Erickson; Peter R Chai; Mariana Matus
Journal:  Prev Chronic Dis       Date:  2020-08-20       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.